CurrentAmbetter NevadaPolicy CP.MP.153

Helicobacter Pylori Serology Testing

Customize your policy alerts

Sign up for Ambetter Nevada Policy CP.MP.153 alerts

Get alerted when Policy CP.MP.153 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

This policy governs the medical necessity and coverage stance for H. pylori serologic antibody testing for members of Ambetter Nevada (Centene-affiliated health plans). It affects providers ordering diagnostic testing for H. pylori infection and evaluating test-of-cure.

Policy Summary

PayerAmbetter Nevada

PolicyHelicobacter Pylori Serology Testing

Policy CodePolicy CP.MP.153

Change TypeNo material change

Effective Date

Next Review Date

Key ActionUse urea breath test or stool antigen testing (stop PPIs as indicated) instead of serology for diagnosis and test-of-cure.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

86677Referenced CPT code

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentAmbetter NevadaPolicy CP.MP.153

Helicobacter Pylori Serology Testing

Customize your policy alerts

Sign up for Ambetter Nevada Policy CP.MP.153 alerts

Get alerted when Policy CP.MP.153 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerAmbetter Nevada

PolicyHelicobacter Pylori Serology Testing

Policy CodePolicy CP.MP.153

Change TypeNo material change

Effective Date

Next Review Date

Key ActionUse urea breath test or stool antigen testing (stop PPIs as indicated) instead of serology for diagnosis and test-of-cure.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

86677Referenced CPT code

Not medically necessary

UBT & stool antigenPreferred tests

ASCP/AGA/ACG citedSociety guidance

Coverage criteria for H. pylori serology

Not Medically Necessary — Serology

Not medically necessary for the following clinical purposes:

Primary restriction: H. pylori serology testing is not medically necessary for diagnosing active H. pylori infection or evaluating treatment effectiveness (test-of-cure).

Serology cannot distinguish active from past infection and cannot be used to confirm eradication; urea breath test and stool antigen testing are preferred for diagnosis and test-of-cure.

Professional societies no longer consider serologic testing appropriate for diagnosing active Helicobacter pylori infection or for confirming eradication. The American Society for Clinical Pathology states that serologic evaluation to determine presence or absence of H. pylori is "no longer considered clinically useful," noting that noninvasive alternatives such as the urea breath test and stool antigen have greater clinical utility, sensitivity, and specificity. The American Gastroenterological Association likewise no longer recommends serology-based testing because it cannot distinguish active from prior exposure, cannot confirm eradication, and has poorer positive predictive value compared with UBT or stool antigen testing.

Professional society guidance supports the policy position that H. pylori serology is not medically necessary for diagnosis or test-of-cure; providers should use validated UBT or stool antigen assays when assessing active infection or confirming eradication.

Serologic antibody testing detects IgG antibodies to H. pylori in serum but cannot distinguish active infection from past exposure and therefore cannot be used as a test-of-cure. Because serology measures prior immune response rather than current bacterial activity, it is less accurate than noninvasive tests that detect active infection—specifically, the urea breath test (UBT) and validated stool antigen tests—which have higher sensitivity and specificity and can be used to confirm eradication after treatment.

For these reasons the policy designates H. pylori serology (CPT 86677) as not medically necessary for diagnosing active infection or evaluating treatment effectiveness; clinicians should prefer UBT or stool antigen testing and follow test-specific preparation and timing recommendations (for example, performing UBT 4–6 weeks after therapy and stopping proton pump inhibitors as indicated).

Relevant billing and diagnosis codes

Referenced CPT CodesCPT

86677

Antibody; Helicobacter pylori

HCPCSHCPCS

No codes listed

ICD-10-CM Diagnosis Codes that Support Coverage CriteriaICD-10

No codes listed

What providers must do (ordering, documentation, prior auth)

Prior Authorization

Prior authorization not supported for CPT 86677

H. pylori serology (CPT 86677) is designated not medically necessary for diagnosing infection or evaluating treatment effectiveness; prior authorization is not supported for those indications.

Referenced CPT: 86677

Step Therapy

Preferred testing sequence: UBT or stool antigen (stop PPIs)

When testing for active H. pylori infection or confirming eradication, use a urea breath test (UBT) or validated stool antigen test instead of serology; stop proton pump inhibitors (PPIs) for at least two weeks before UBT or stool antigen testing per test instructions.

UBT is the noninvasive test of choice with high sensitivity and specificity and appropriate for test-of-cure when performed 4–6 weeks after therapy.
Stool antigen tests using validated monoclonal assays are as accurate as UBT and can be used as a test-of-cure; PPIs should be stopped for two weeks before testing.

Clinical background

Helicobacter pylori is a common chronic bacterial infection and a leading cause of peptic ulcer disease, chronic gastritis, and is associated with gastric adenocarcinoma and MALT lymphoma. Accurate diagnosis is important because H. pylori causes progressive gastroduodenal injury; noninvasive testing options include the urea breath test, stool antigen test, and serology, but UBT and stool antigen are the most accurate and are suitable for confirming eradication while serology cannot distinguish active from past infection.

Test definitions and characteristics

Serologic antibody testing — definition and limitations

DefinitionSerologic antibody testing detects immunoglobulin G (IgG) antibodies to Helicobacter pylori in serum, most commonly using ELISA-based methods.

Limitation — cannot distinguish active vs past infectionSerologic testing cannot differentiate active H. pylori infection from prior exposure or past infection; it detects host antibody response rather than active organisms.

Not suitable as test-of-cureAntibody persistence after eradication means serology cannot be used to confirm eradication or as a test-of-cure.

Accuracy considerationsSerology is less accurate than UBT or stool antigen testing; predictive values vary with population prevalence and pretest probability (higher false positives in low-prevalence settings).

Urea breath test (UBT) — definition and role

Definition

Policy Summary

PayerAmbetter Nevada

PolicyHelicobacter Pylori Serology Testing

Policy CodePolicy CP.MP.153

Change TypeNo material change

Effective Date

Next Review Date

Key ActionUse urea breath test or stool antigen testing (stop PPIs as indicated) instead of serology for diagnosis and test-of-cure.

SourceLink

On This Page

Documentation Required

Document preferred noninvasive test and PPI washout

Document use of preferred noninvasive testing (UBT or stool antigen) when diagnosing active H. pylori infection or confirming eradication, and record adherence to test instructions including discontinuation of PPIs for the required washout period.

If UBT is used as test-of-cure, document that it was performed 4–6 weeks after completion of therapy.
Document PPI discontinuation for at least two weeks prior to UBT or stool antigen testing when applicable.

Denial Risk

Denial risk: serology not medically necessary for diagnosis or test-of-cure

Claims for H. pylori serology testing are not considered medically necessary for diagnosing infection or evaluating treatment effectiveness and may be denied if submitted for diagnosis or test-of-cure purposes.

Serologic antibody testing cannot distinguish active from past infection and cannot be used to confirm eradication, supporting denial risk for diagnostic or test-of-cure claims.

Urea breath test (UBT) is a noninvasive diagnostic test in which the patient ingests urea labeled with carbon-13 or carbon-14; H. pylori urease activity breaks down the labeled urea and labeled CO2 is measured in exhaled breath.

Role — preferred noninvasive testUBT is the noninvasive test of choice for detecting active H. pylori infection, with high sensitivity (88%–95%) and specificity (95%–100%).

Use as test-of-cureUBT can be used to confirm eradication when performed 4–6 weeks after completion of therapy; proton pump inhibitors should be stopped for at least two weeks before testing.

LimitationsAccuracy is lower in patients who have had distal gastrectomy and influenced by recent PPI use if not withheld per instructions.

Stool antigen test — definition and role

DefinitionStool antigen testing uses monoclonal antibody assays on fecal specimens to detect H. pylori antigens as evidence of active infection.

Role — noninvasive test and test-of-cure alternativeWhen a validated laboratory-based monoclonal assay is used, stool antigen testing is generally as accurate as UBT and can be used to confirm eradication (test-of-cure).

PPIs and timingPPIs should be stopped for two weeks prior to stool antigen testing; stool antigen tests are less affected by PPI use than UBT but accuracy still improves when PPIs are withheld.